A pretreatment transcriptomic signature that predicts outcomes of immunotherapy in melanoma

Identifying indicators of immunotherapy response are key to clinical treatment decisions. To date, immunotherapy is most widely used in melanoma because of its higher tumor mutation burden compared to other cancer types. However, less than half of melanoma patients can benefit from immune checkpoint...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Junjie, Liu, Bei, Hu, Wangxiong, Yang, Yanmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813707/
https://www.ncbi.nlm.nih.gov/pubmed/36619423
http://dx.doi.org/10.1016/j.heliyon.2022.e12648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813707/
https://www.ncbi.nlm.nih.gov/pubmed/36619423
http://dx.doi.org/10.1016/j.heliyon.2022.e12648

Ejemplares similares